Euthymics Bioscience

Developing next-gen treatments for depression targeting those unmet by SSRIs

Founded 2009 Series A Total: $38.50M Biotechnology, Pharmaceutical

Euthymics Bioscience is a neuroscience-focused clinical-stage company founded in 2009. The company's slogan "Developing next-gen treatments for depression targeting those unmet by SSRIs" encapsulates its primary goal of developing next-generation treatments for depression, with a focus on patients who do not respond adequately to SSRIs. Their lead product, EB-1010, aims to improve efficacy and minimize the chief side effects associated with standard antidepressants, such as weight gain, sexual dysfunction, and cognitive impairment. Based in Cambridge, Massachusetts, Euthymics Bioscience operates as a private Delaware corporation. Its areas of focus encompass central nervous system disorders, particularly major depressive disorder (MDD) and, in collaboration with the government, alcohol use disorder (AUD). These disorders have significant unmet medical needs, with MDD impacting over 15 million American adults, according to the National Institutes of Health. The National Institute of Alcohol Abuse and Alcoholism (NIAAA) reports that roughly 18 million Americans suffer from AUD. Euthymics Bioscience secured a $10.50M Series A investment on 01 April 2014, signifying external validation of its potential. As a company operating in the Biotechnology and Pharmaceutical industries, Euthymics Bioscience holds promise in addressing critical unmet needs in the treatment of depression and related disorders.

Funding Stage	Amount	Investors	Lead Investors	Date
Series A	$10.50M	-		01 Apr 2014
Series A	$4.00M	4	Novartis Venture Fund, GBS Ventures +2	09 Mar 2011
Series A	$24.00M	3	Novartis Venture Fund, GBS Ventures +1	22 Jul 2010

Funding Stage

Amount

Investors

Lead Investors

Date

Series A

$10.50M

01 Apr 2014

Series A

$4.00M

Novartis Venture Fund, GBS Ventures +2

09 Mar 2011

Series A

$24.00M

Novartis Venture Fund, GBS Ventures +1

22 Jul 2010

FAQ About Euthymics Bioscience

Developing next-gen treatments for depression targeting those unmet by SSRIs

Euthymics Bioscience was founded in 2009.

Euthymics Bioscience operates in Biotechnology and Pharmaceutical. Its work centres on neuroscience, clinical-stage company, depression treatment and SSRI non-responders.

Euthymics Bioscience has completed 3 funding rounds, raising a total of $38.50M. The latest funding stage is Series A.

Top alternatives and competitors to Euthymics Bioscience include Vistagen, Seelos Therapeutics, Inc., Acadia Pharmaceuticals, Relmada Therapeutics, Inc, Emalex Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Euthymics Bioscience and Vistagen are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Euthymics Bioscience

Funding Rounds & Investors (3)

Euthymics Bioscience Alternatives & Competitors

FAQ About Euthymics Bioscience